SG Americas Securities
CNCE

SG Americas Securities’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

SG Americas Securities’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,361
Closed -$119K – 3652
2022
Q4 		$119K Buy
20,361
+3,352
+20% +$17.6K ﹤0.01% 2604
2022
Q3 		$114K Buy
+17,009
New +$103K ﹤0.01% 2765
2020
Q3 		– Sell
-15,686
Closed -$156K – 3678
2020
Q2 		$156K Buy
+15,686
New +$150K ﹤0.01% 3070
2017
Q4 		– Sell
-10,367
Closed -$153K – 3755
2017
Q3 		$153K Buy
+10,367
New +$150K ﹤0.01% 2825

SG Americas Securities's CNCE Position: Q1 2023 in Review

SG Americas Securities sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 20,361 shares — an estimated $119K sold.

SG Americas Securities first reported a position in CNCE in Q3 2017 and held it in 4 quarters. The position peaked at $156K in Q2 2020. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

  • SG Americas Securities reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • SG Americas Securities sold 20,361 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $119K.
  • SG Americas Securities first reported a position in Concert Pharmaceuticals, Inc. in Q3 2017 and held it in 4 quarters.
  • SG Americas Securities's Concert Pharmaceuticals, Inc. position peaked at $156K in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on SG Americas Securities's 13F filing for Q1 2023, filed 28 Apr 2023.